Loading...
Receive $200 for creating an Interactive Brokers account using our link: Create IBKR account. Read our Interactive Brokers analysis
- Ticker
- ENLV
- Price
- 1.10
- Stock movement down
- -0.01 (-0.90%)
- Company name
- Enlivex Therapeutics Ltd
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 261.12M
- Ent value
- 260.38M
- Price/Sales
- -
- Price/Book
- 14.94
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -39.02%
- 1 year return (CAGR)
- 5.77%
- 3 year return (CAGR)
- -37.00%
- 5 year return (CAGR)
- -46.02%
- 10 year return (CAGR)
- -37.28%
Last updated: 2026-02-20
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
ENLV does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | - |
| Price to Book | 14.94 |
| EV to Sales | - |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 237.38M |
| EPS (TTM) | -0.53 |
| FCF per share (TTM) | -0.51 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 0.00 |
| Gross profit (TTM) | -256.00K |
| Operating income (TTM) | -14.04M |
| Net income (TTM) | -12.70M |
| EPS (TTM) | -0.53 |
| EPS (1y forward) | -0.32 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | - |
| Profit margin (TTM) | - |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.20M |
| Net receivables | 567.00K |
| Total current assets | 19.50M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 4.78M |
| Total assets | 20.94M |
| Accounts payable | 375.00K |
| Short/Current long term debt | 701.00K |
| Total current liabilities | 3.03M |
| Total liabilities | 3.46M |
| Shareholder's equity | 17.48M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -12.23M |
| Capital expenditures (TTM) | 97.55K |
| Free cash flow (TTM) | -12.33M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -72.66% |
| Return on Assets | -60.66% |
| Return on Invested Capital | -71.53% |
| Cash Return on Invested Capital | -69.42% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.09 |
| Daily high | 1.12 |
| Daily low | 1.08 |
| Daily Volume | 130K |
| All-time high | 391.60 |
| 1y analyst estimate | 13.00 |
| Beta | 1.59 |
| EPS (TTM) | -0.53 |
| Dividend per share | 0.00 |
| Ex-div date | - |
| Next earnings date | 25 Feb 2026 |
Downside potential
Loading...
Downside potential data
| ENLV | S&P500 | |
| Current price drop from All-time high | -99.72% | -1.82% |
| Highest price drop | -99.83% | -56.47% |
| Date of highest drop | 30 Dec 2025 | 9 Mar 2009 |
| Avg drop from high | -88.28% | -10.84% |
| Avg time to new high | 264 days | 12 days |
| Max time to new high | 2885 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
261.12M
Marketcap category
Small-cap
Description
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Employees
0
Website
Investor relations
-
SEC filings
CEO
Oren Hershkovitz
Country
USA
City
Nes-Ziona
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page